The incidence of infections due to extended-spectrum b-lactamase (ESBL)-producing Escherichia coli and
tance in Escherichia coli and Klebsiella pneumoniae is of great concern, because these organisms are extremely common nosocomial pathogens [4] . In addition, because ESBL-producing E. coli and K. pneumoniae (ESBL-EK) isolates are frequently resistant to multiple antimicrobial agents, therapeutic options for these infections are severely limited. To date, the agents to which ESBL-EK infections are most reliably susceptible are the carbapenems, imipenem and meropenem. However, increased empirical use of imipenem in response to outbreaks of ESBL-EK infection has been associated with the rapid emergence of imipenem resistance in other nosocomial pathogens [5, 6] .
When ESBL-EK isolates are susceptible to the fluoroquinolones, treatment with these agents has been effective [7] . However, recent studies have demonstrated that 40%-45% of such isolates are resistant to fluoroquinolones [3, 8] . Identification of risk factors for fluor-oquinolone-resistant ESBL-EK infection is essential in exploring possible explanations for the emergence of fluoroquinolone resistance in these infections. Furthermore, such information would be vital in identifying factors that could be modified to bring about a decrease in fluoroquinolone resistance and preserve the role of these agents in the treatment of ESBL-EK infections. This would subsequently help to reduce the dependence on carbapenem agents and limit the emergence of carbapenem resistance.
Beginning in June 1997, we noted a marked increase in the number of ESBL-EK infections at 2 hospitals in the University of Pennsylvania Health System. During the next 16 months, 102 such pathogens were isolated. We conducted the current study to identify risk factors for fluoroquinolone resistance in ESBL-EK infections. In addition, we evaluated the evidence for clonal spread of fluoroquinolone resistance among ESBL-EK isolates.
METHODS

Subjects.
This investigation was conducted at 2 hospitals in the University of Pennsylvania Health System: the Hospital of the University of Pennsylvania (HUP), a 725-bed academic tertiary-care medical center, and Presbyterian Medical Center (PMC), a 344-bed urban community hospital.
All cultures that demonstrated an ESBL-EK isolate were identified through records of the Clinical Microbiology Laboratory at HUP, which processes and cultures all specimens obtained at HUP and PMC. All patients who had cultures that were positive for an ESBL-EK organism from 1 June 1997 through 30 September 1998 were eligible for inclusion in the study. Only those patients who met the Centers for Disease Control and Prevention criteria for infection were included [9] . Each patient was included in the study only once. If an ESBL-EK isolate was recovered on multiple occasions, only the first episode of infection was reviewed.
Data collection. To assess risk factors for fluoroquinolone resistance among ESBL-EK infections, a retrospective casecontrol study was conducted. Designation as a case patient or control patient was based solely on whether the patient's infecting ESBL-EK organism was found to demonstrate fluoroquinolone resistance. Potential risk factors for fluoroquinolone resistance were ascertained through review of inpatient medical records. Data obtained included age, sex, race, hospital location, number of hospital days before infection, number of days in an intensive care unit in the prior 30 days, and severity of illness, as calculated by the Acute Physiology and Chronic Health Evaluation (APACHE) II score [10] . In addition, the presence of a central venous catheter, urinary catheter, or mechanical ventilation was assessed. Finally, the presence of diarrhea at the time of infection was ascertained.
The anatomic site of infection, antimicrobial susceptibility profile of the infecting organism, and presence of any coinfecting organism(s) were documented. The presence of the following comorbid conditions was documented: hepatic dysfunction, malignancy, diabetes mellitus, renal insufficiency, HIV infection, neutropenia, corticosteroid use, prior organ transplant, use of an immunosuppressive agent in the 30 days prior to recovery of an isolate, and surgical procedure or trauma in the 30 days prior to recovery of an isolate. Finally, all antimicrobial therapy in the 30 days prior to recovery of an isolate was documented.
Nosocomial infection was defined as infection that occurred 148 h after admission to the hospital; infection that occurred р48 h after admission, in patients who were hospitalized within the 2 weeks prior to current hospital admission; or infection that occurred р48 h after admission, in patients who were transferred from an outside hospital or long-term care facility (LTCF). Hepatic dysfunction was defined by the presence of у2 of the following: a bilirubin concentration of 12.5 mg/dL, an aspartate aminotransferase or alanine aminotransferase level more than twice normal, or known liver disease. Neutropenia was classified as an absolute neutrophil count of !500 cells/ mm 3 , and renal insufficiency was indicated by a creatinine level of 12.0 mg/dL or the requirement of dialysis. Corticosteroid use was defined as the receipt of prednisone at a dosage of у20 mg/day (or equivalent) for у2 weeks.
Microbiological methods. Susceptibilities to all antimicrobial agents were determined according to criteria of the National Committee for Clinical Laboratory Standards [11] , by means of either a semiautomated system (MicroScan WalkAway System, NC16 panel; Dade Behring) or disk-diffusion susceptibility testing. An ESBL-EK isolate was considered fluoroquinolone resistant if it demonstrated an MIC of levofloxacin of у8 mg/mL [11] . Resistance to levofloxacin was considered an indicator of resistance to all fluoroquinolones [12] . E. coli and K. pneumoniae isolates with MICs of ceftazidime and/or aztreonam of 12 mg/mL were suspected of producing an ESBL or AmpC-type b-lactamase. Such isolates were subjected to the double disk-diffusion test, as described by Thomson and Sanders [13] , but with the ceftazidime and amoxicillin-clavulanic acid disks placed 15 mm apart. Any distortion of the zone around the ceftazidime disk toward the amoxicillin-clavulanic acid disk was considered to be positive for ESBL production. AmpC-type b-lactamase production was suspected in isolates that had an elevated MIC of ceftazidime (12 mg/mL) and that were resistant to both amoxicillin-clavulanic acid and cefoxitin.
Isolates that demonstrated an AmpC-type b-lactamase phenotype were also classified as ESBLs. Selected isolates were evaluated for relatedness by genomic analysis with pulsed-field gel electrophoresis (PFGE) [14] . PFGE data were interpreted according to established guidelines [15] . Statistical analysis. Bivariable analysis was conducted to determine the association between potential risk factors and fluoroquinolone-resistant ESBL-EK infection. Categorical variables were compared by means of either x 2 analysis or Fisher's exact test when needed. An OR and 95% CI were calculated to evaluate the strength of any association. Continuous variables were compared by use of Student's t test or the Wilcoxon rank sum test, depending on the validity of the normality assumption [16] .
Multivariable analysis was done using multiple logistic regression [17] . All variables with a P value of р.15 on bivariable analysis were considered for inclusion in a multivariable explanatory model. Building of the multivariable model began with inclusion of certain key variables based on a priori hypotheses (i.e., prior fluoroquinolone use, LTCF residence) as well as variables (e.g., age, sex) believed likely to influence the association between the key variables and the outcome of interest. In addition, variables were also considered in building a model if they were noted to be involved in confounding or interaction on stratified analysis. The interaction between risk factor variables was also investigated.
ORs that are calculated using multiple logistic regression are often interpreted as an approximation of the risk ratio. However, only when the incidence of the outcome in the study population is low (!10%) does the OR closely approximate the risk ratio. In this study, the incidence of the outcome of interest (fluoroquinolone resistance) was 150%, thus making the OR a poor approximation of the risk ratio. To aid the interpretation of the magnitude of the associations, selected adjusted ORs derived from multivariable analysis were converted to risk ratios by the method described by Zhang and Yu [18] .
A 2-tailed P value of !.05 was considered significant. All statistical calculations were done using standard programs in STATA, version 5.0 (STATA Corp).
RESULTS
During the 16-month study period, 102 ESBL-EK isolates were identified in clinical specimens obtained at HUP and PMC, representing ∼5.5% of all inpatient E. coli and K. pneumoniae isolates. Of the 102 patients, 89 (87.3%) fulfilled criteria for infection [9] . Of these, 77 patients (86.5%) had complete medical records available for review.
The median age of patients was 69 years (range, 17-95 years). The percentages of patients who were African American, white, and Latino were 64.9%, 35.1%, and 1.3%, respectively. Thirtynine patients (50.6%) were hospitalized at HUP and 38 patients (49.4%) were hospitalized at PMC.
Forty-nine infections (63.6%) were due to K. pneumoniae and 28 (36.4%) were due to E. coli. Sixty-four ESBL-EK infections (83.1%) were nosocomial, and 19 (24.7%) were polymicrobial. The site of infection among the 77 patients was urinary for 47 patients (61.0%), wound for 8 (10.4%), central venous catheter for 8 (10.4%), respiratory for 7 (9.1%), blood for 6 (7.8%), and abdominal for 1 (1.3%). For 20 patients (26.0%), there was bloodstream involvement.
Of the 77 ESBL-EK infections, 43 (55.8%) were fluoroquinolone resistant. Of note, among all inpatient E. coli and K. pneumoniae isolates obtained during the same time period, ∼5.1% and 7.4%, respectively, were fluoroquinolone resistant.
Imipenem was the only antibacterial agent to which all ESBL-EK isolates were susceptible. Of those agents to which at least one-half of all isolates were tested, the percentages of isolates demonstrating susceptibility were as follows: levofloxacin, 43.8%; amikacin, 43.5%; tetracycline, 32.5%; gentamicin, 27.0%; tobramycin, 24.4%; and cotrimoxazole, 19.6%. There were no consistent differences in the susceptibility of ESBL-EK isolates to other antimicrobial agents when fluoroquinoloneresistant and fluoroquinolone-susceptible isolates were compared (figure 1).
Although there were no significant differences in general characteristics of case patients and control patients, patients with fluoroquinolone-resistant ESBL-EK infections were more frequently hospitalized at PMC (55.8% vs. 41.2%) and admitted from an LTCF (37.2% vs. 23.5%) than were control patients (table 1) . In a comparison of the hospital location of the 2 groups, patients with fluoroquinolone-resistant ESBL-EK infections were more likely to have been located in a medical intensive care unit than were control patients (table 2) . There were no differences between groups regarding comorbid conditions and the anatomic site of infection (table 2) . No patient in either group had HIV infection or neutropenia.
Although there were no significant differences between groups with regard to general antibacterial use (either total number of antibacterial agents used or total antibacterial-days), there were differences in use of specific antimicrobial agents (table 3) . Patients with fluoroquinolone-resistant ESBL-EK in- fections were more likely to have received a fluoroquinolone or aminoglycoside in the preceding 30 days. LTCF residence was much more common among patients admitted to PMC than it was among those admitted to HUP (55.3% and 7.8%, respectively). Admitting hospital was not, however, a confounder or effect modifier in any of the associations between fluoroquinolone-resistant ESBL-EK infection and fluoroquinolone use, aminoglycoside use, or LTCF residence. Furthermore, LTCF residence was not involved in confounding or effect modification in the association between fluoroquinolone or aminoglycoside use and fluoroquinoloneresistant ESBL-EK infection.
The final multivariable model included 3 variables that were associated with fluoroquinolone-resistant ESBL-EK infection: prior fluoroquinolone use, prior aminoglycoside use, and LTCF residence (table 4). The adjusted ORs for these variables were then converted to risk ratios [18] . The calculated risk ratios for prior fluoroquinolone use, prior aminoglycoside use, and LTCF residence were 1.90, 1.71, and 1.51, respectively. The final model also included the variables of age and sex.
PFGE analysis was done on all available ESBL-EK organisms isolated at HUP from June 1997 through May 1998 [19] . Of 33 ESBL-EK infections during the 12-month period, 22 isolates were available for PFGE analysis, including 16 isolates of K. pneumoniae and 6 isolates of E. coli. Of the 16 K. pneumoniae isolates, 6 were fluoroquinolone resistant; of these 6 isolates, 3 demonstrated a close relationship (!4 bands difference). Three of the 6 E. coli isolates were noted to be fluoroquinolone resistant; of these 3 isolates, 2 demonstrated a clonal relationship.
DISCUSSION
We found a high prevalence of fluoroquinolone resistance in patients with ESBL-EK infections. Three variables were independent risk factors for fluoroquinolone resistance: fluoroquinolone exposure, aminoglycoside exposure, and residence in an LTCF.
The association between fluoroquinolone use and fluoroquinolone-resistant ESBL-EK infection confirms in vitro studies that have demonstrated the selection of high-level fluoroquinolone resistance by serial passage of organisms through increasing concentrations of the drug [20] . Similar associations have also been noted in non-ESBL-producing E. coli infections [21] . Our results strongly suggest that the general use of fluoroquinolones be closely monitored to ensure appropriateness of use, particularly given recent findings that a fluoroquinolone agent was considered a first-line agent among only 29% of the patients in which it was used [22] .
We also found that prior use of an aminoglycoside was significantly associated with fluoroquinolone-resistant ESBL-EK infection. In vitro studies noted that exposure of E. coli to other antibacterial agents can select mutants with low-level fluoroquinolone resistance [23] . It has also been suggested that exposure to such antibacterial agents as cotrimoxazole and aminoglycosides may cause alterations in membrane permeability, resulting in concurrent fluoroquinolone resistance [24] . Of note, a recent study found that aminoglycoside exposure was significantly associated with fluoroquinolone-resistant Pseudomonas aeruginosa bloodstream infection [25] . Although these results should be confirmed in larger studies, our data suggest that aminoglycoside use should also be carefully scrutinized to prevent inappropriate use and overuse.
Although we identified a significant association between the use of 2 specific antibacterial agents and fluoroquinolone-resistant ESBL-EK infection, 150% of patients with ESBL-EK infections had not been exposed to either agent. One explanation for this may be that these patients acquired resistant infections through person-to-person spread. We noted similarities in the PFGE restriction patterns of many of the fluoroquinolone-resistant ESBL-EK organisms, raising the possibility of nosocomial spread of these organisms. The association between LTCF residence and fluoroquinolone-resistant ESBL-EK infection also supports the possibility of person-to-person spread of resistance, because LTCF patients have greater exposure to infected or colonized patients and because such centers often have limited infection control programs [26] . These results further emphasize the importance of barrier precautions in limiting the spread of resistant infections. Implementation of such precautions for patients with ESBL-EK infections has been shown to play a vital role in limiting the spread of such outbreaks [1] . Whether such interventions will be effective in limiting the spread of fluoroquinolone resistance in such isolates deserves further study.
The marked increase in the incidence of ESBL-EK infections in recent years is of great concern, given that E. coli and K. pneumoniae account for 120% of all nosocomial infections [4] . Because carbapenems are the only antimicrobial agents to which ESBL-EK isolates have not yet demonstrated widespread resistance [1, 8] , ever greater dependence is being placed on these agents for both empirical and definitive treatment of these multidrug-resistant infections. These trends have been complicated by the emergence of carbapenem resistance in other nosocomial pathogens [5, 6] . It has also recently been noted that carbapenem resistance may arise in ESBL-EK isolates through high-level expression of an AmpC-type b-lactamase in combination with the loss of a major outer membrane protein [27, 28] . Selective pressure from escalating use of these agents is likely to make the occurrence of such isolates increasingly common. For these reasons, it is essential to preserve the role of alternative agents that are effective against ESBL-EK infections. Although carbapenems are the agents of choice in suspected ESBL-EK infection, when ESBL-EK isolates are susceptible to fluoroquinolones, fluoroquinolones are effective [7] . However, recent reports have demonstrated that as many as 45% of ESBL-EK infections may be fluoroquinolone resistant [3, 8] . Identification of risk factors for fluoroquinolone resistance in ESBL-EK infections provides vital information regarding possible interventions designed to curb the increase in fluoroquinolone resistance and preserve these agents as a viable therapeutic option, thereby reducing the dependence on carbapenems.
There were several potential limitations to our study. Although the possibility of selection bias is normally of concern in a case-control study, all case patients and control patients were identified through the same microbiology laboratory that processes all bacterial cultures for the participating institutions. All eligible case patients and control patients were included in the study. Thus, the potential for selection bias in the risk factor analysis was likely small, except for that which was introduced through lost charts. The potential for selection bias is also of concern in the PFGE analysis of this study. Because this analysis was not done on all isolates, firm conclusions regarding the importance of acquisition versus horizontal spread of fluoroquinolone resistance cannot be drawn from those data.
Although retrospective chart review studies may be limited by the availability of medical records, we found that 85% of charts were complete and available for review. Whereas information concerning in-hospital antibacterial use was available from the medical record, the possibility exists for inaccuracies in data regarding antibacterial use at an outside hospital, at an LTCF, or as an outpatient. Future studies should seek to elucidate the association between fluoroquinolone use and fluoroquinolone resistance in the LTCF and community setting. Finally, we limited our analysis of antibacterial use to 30 days before infection and were thus unable to assess possible associations between fluoroquinolone-resistant ESBL-EK infection and more remote antibacterial use. Finally, our study was conducted in a large academic tertiary-care medical center and a smaller urban community hospital, and the results may thus not be generalizable to other institutions.
In conclusion, we investigated the epidemiology of fluoroquinolone resistance in ESBL-EK infections and found 3 independent risk factors for fluoroquinolone resistance: fluoroquinolone use, LTCF residence, and aminoglycoside use. Our results suggest that strategies designed to curb the increase in fluoroquinolone resistance should focus on limiting the use of fluoroquinolone and aminoglycoside antibacterial agents and emphasizing barrier precautions in patients who are infected or colonized with such isolates. Preserving the usefulness of fluoroquinolones in the treatment of ESBL-EK infections will reduce the current dependence on the carbapenem agents and limit the potential for further emergence of carbapenem resistance in both ESBK-EK isolates and other nosocomial pathogens. Future studies should seek to prospectively validate these findings, particularly in patients residing in LTCFs, and evaluate the impact of interventions designed to decrease fluoroquinolone resistance in ESBL-EK infections.
